PATENT CLAIM ANALYSIS

Application Number: 15926076
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "220000"]

Abstract:
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Claim (Index 31):
The method of  claim 30 , wherein the at least one biodegradable polymer is a poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly-1-lactic acid, poly-d-lactic acid, poly(glycolic acid), copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-captolactone), poly(amino acid), polyesteramide, polyanhydrides, polyphosphazines, poly(alkylene alkylate), biodegradable polyurethane, polyvinylpyrrolidone, polyalkanoic acid, polyethylene glycol, copolymer of polyethylene glycol and polyorthoester, albumin, chitosan, casein, waxes or blends or copolymers thereof.

Metadata:
- Claim Count in Document: 164.0
- Percentile: 90.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14995658', '15101874', '11274887', '14714621', '14773642']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7174737753607361
- 35 USC 102 Novelty (BERT): 0.4953647373327596
- Combined Prediction Score: 0.6952628715579384
- Mean Citation Score: 173.36240800000004
- Max Citation Score: 178.04628
- Similarity Product: 121.1747407945776

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test